Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 25 vs ENZALUTAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Treatment of metastatic castration-resistant prostate cancer,Treatment of metastatic castration-sensitive prostate cancer
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
160 mg orally once daily
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Terminal elimination half-life is approximately 5.8 days (range 2.8–10.2 days) after steady state; supports once-daily dosing.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Primarily metabolized by CYP2C8 and CYP3A4; forms active metabolite N-desmethyl enzalutamide
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Primarily hepatic metabolism; ~70% of dose excreted in feces (as unchanged drug and metabolites), ~1% in urine as unchanged drug. Biliary excretion is a major route.
97–99% (sex hormone-binding globulin and albumin)
97–98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Approximately 110 L (1.1 L/kg for a 70 kg patient); indicates extensive extravascular distribution.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Oral bioavailability is not published; absorption is at least moderate based on systemic exposure. Food does not significantly affect absorption.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). Insufficient data for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
No dose adjustment for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B): reduce dose to 80 mg once daily. Not recommended for severe (Child-Pugh C).
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Not approved for use in pediatric patients; safety and efficacy not established.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
No specific dose adjustment required; elderly patients may be more susceptible to adverse effects such as falls, fractures, and hypertension. Monitor closely.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
None
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Seizure risk,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions including angioedema,Increased risk of falls and fractures,Embryo-fetal toxicity
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
Pregnancy,Concomitant use with strong CYP2C8 inhibitors or inducers,Concomitant use with strong CYP3A4 inducers
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No significant food interactions. Avoid grapefruit juice as it may increase enzalutamide levels (minor interaction). Take with or without food.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphroditism and impaired reproductive development. Use should be avoided in all trimesters. Women of childbearing potential must use effective contraception during treatment and for 1 month after the last dose.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
No human data available. Enzalutamide and its active metabolite are likely excreted into human milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 1 month after the last dose. M/P ratio is unknown.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
Enzalutamide is contraindicated in pregnancy; therefore, no dose adjustments are recommended. If exposure occurs, discontinue the drug and manage according to clinical judgment. Pregnancy induces metabolic changes (e.g., increased hepatic clearance, plasma volume expansion) that could theoretically reduce exposure, but no data exist to support a specific dose adjustment.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Monitor for seizure risk, especially in patients with predisposing factors; enzalutamide may cause hypertension, so check blood pressure regularly; it significantly induces CYP3A4, reducing efficacy of oral contraceptives and other CYP3A4 substrates; use with caution in patients with history of cardiovascular disease; discontinue 5 half-lives before starting another antiandrogen.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
Take the capsules whole, with or without food, at the same time each day.,Do not crush, chew, or open the capsules.,Report any signs of seizure (e.g., convulsions, loss of consciousness) to your doctor immediately.,Enzalutamide may raise your blood pressure; have it checked regularly.,Use effective non-hormonal contraception during treatment and for 3 months after stopping; hormonal contraceptives may not work.,This drug may cause fatigue, falls, and fractures; avoid activities requiring alertness until you know how it affects you.,Notify your doctor if you experience chest pain, shortness of breath, or leg swelling.,Seek immediate medical attention for symptoms of posterior reversible encephalopathy syndrome (PRES): headache, confusion, visual disturbances.
No interactions on record
"Rifaximin is a non-systemic antibiotic with minimal oral absorption (<0.4%), thus is not expected to significantly affect systemic drug metabolism. However, in vitro studies suggest rifaximin can induce the expression of CYP3A4, the major enzyme responsible for the metabolism of enzalutamide. Although clinical data are limited, coadministration could theoretically decrease enzalutamide exposure, reducing its efficacy in treating prostate cancer; conversely, the baseline description suggests an increase, but evidence is conflicting."
"Enzalutamide, a potent CYP3A4 inducer, significantly reduces the exposure of diclofenac, a CYP2C9 substrate, by increasing its hepatic metabolism. This interaction can lead to subtherapeutic diclofenac concentrations, thereby diminishing its analgesic and anti-inflammatory efficacy. Clinically, patients may experience inadequate pain control or exacerbation of inflammatory conditions, such as arthritis, when these agents are coadministered."
"Enzalutamide, a potent androgen receptor inhibitor, significantly induces CYP3A4 and other drug-metabolizing enzymes. Dienogest, a progestin used in endometriosis and contraception, is primarily metabolized by CYP3A4. Coadministration leads to markedly reduced dienogest plasma concentrations, potentially diminishing its therapeutic efficacy in managing endometriosis symptoms or contraceptive effectiveness."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 25 vs ENZALUTAMIDE, answered by our medical review team.
ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. ENZALUTAMIDE is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits androgen receptor nuclear translocation, DNA binding, and coactivator recruitment.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 25 and ENZALUTAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. The standard adult dose of ENZALUTAMIDE is: 160 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 25 and ENZALUTAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. ENZALUTAMIDE is classified as Category D/X. Enzalutamide is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibitor), there is a high risk of fetal harm, particularly male pseudohermaphrod. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.